Candel Therapeutics, Inc.

NASDAQ:CADL

5.09 (USD) • At close November 7, 2024
Bedrijfsnaam Candel Therapeutics, Inc.
Symbool CADL
Munteenheid USD
Prijs 5.09
Beurswaarde 163,311,632
Dividendpercentage 0%
52-weken bereik 0.77 - 14.3
Industrie Biotechnology
Sector Healthcare
CEO Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
Website https://www.candeltx.com

An error occurred while fetching data.

Over Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for

Vergelijkbare Aandelen

Champions Oncology, Inc. logo

Champions Oncology, Inc.

CSBR

4.32 USD

Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc.

TCRT

2.02 USD

TELA Bio, Inc. logo

TELA Bio, Inc.

TELA

2.99 USD

Immuneering Corporation logo

Immuneering Corporation

IMRX

1.93 USD

Leap Therapeutics, Inc. logo

Leap Therapeutics, Inc.

LPTX

3.47 USD

KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc.

KRMD

2.82 USD

Anixa Biosciences, Inc. logo

Anixa Biosciences, Inc.

ANIX

3.62 USD

Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc.

TSHA

1.42 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)